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Metabolically healthy obesity: facts and fantasies
Gordon I. Smith, Bettina Mittendorfer, and Samuel Klein
Center for Human Nutrition, Washington University School of Medicine, St. Louis, Missouri, USA.

Although obesity is typically associated with metabolic dysfunction and cardiometabolic diseases, some people with obesity
are protected from many of the adverse metabolic effects of excess body fat and are considered “metabolically healthy.”
However, there is no universally accepted definition of metabolically healthy obesity (MHO). Most studies define MHO as
having either 0, 1, or 2 metabolic syndrome components, whereas many others define MHO using the homeostasis model
assessment of insulin resistance (HOMA-IR). Therefore, numerous people reported as having MHO are not metabolically
healthy, but simply have fewer metabolic abnormalities than those with metabolically unhealthy obesity (MUO). Nonetheless,
a small subset of people with obesity have a normal HOMA-IR and no metabolic syndrome components. The mechanism(s)
responsible for the divergent effects of obesity on metabolic health is not clear, but studies conducted in rodent models
suggest that differences in adipose tissue biology in response to weight gain can cause or prevent systemic metabolic
dysfunction. In this article, we review the definition, stability over time, and clinical outcomes of MHO, and discuss the
potential factors that could explain differences in metabolic health in people with MHO and MUO —
 specifically, modifiable
lifestyle factors and adipose tissue biology. Better understanding of the factors that distinguish people with MHO and MUO
can produce new insights into mechanism(s) responsible for obesity-related metabolic dysfunction and disease.

Introduction

Obesity is often associated with a constellation of metabolic abnormalities, including insulin resistance, prediabetes, atherogenic dyslipidemia (high plasma triglyceride [TG] and low HDL-cholesterol
[HDL-C] concentrations), nonalcoholic fatty liver disease, and the
metabolic syndrome, which are important risk factors for type 2
diabetes (T2D) and cardiovascular diseases (CVDs) (1, 2). However, not all people with obesity have metabolic complications, raising the question of whether those who are metabolically healthy
represent a unique subset of people with obesity or are simply a
group that is in transition to developing metabolically unhealthy
obesity (MUO) later. In this article, we explore the premise that
very few people with obesity are truly metabolically healthy, and
evaluate putative modifiable factors (diet, physical activity, and
sleep) and adipose tissue factors involved in determining the metabolic effects of excessive adiposity. To this end, we will provide a
background to review the definition, prevalence, stability, and clinical outcomes of metabolically healthy obesity (MHO), followed by
a discussion of potential factors that could explain the differences
in metabolic health in people with MHO and MUO.

Definition of metabolically healthy obesity

There is no universally accepted standard for defining MHO, and
more than 30 different definitions have been used in different
studies (ref. 3 and Table 1). In most studies, MHO was defined as
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having ≤2 of the following five metabolic syndrome components:
high systolic and diastolic blood pressures, high plasma TG concentration, low HDL-C concentration, high fasting blood glucose, and a large waist circumference; or ≤1 abnormal component
excluding waist circumference (4). Additional criteria, including
high plasma total cholesterol, LDL-cholesterol, and C-reactive
protein concentrations, 2-hour blood glucose concentrations
during an oral glucose tolerance test, and indices of insulin sensitivity/resistance (based on the homeostasis model assessment
of insulin resistance [HOMA-IR] score [ref. 5], the Matsuda index
[an index of whole-body insulin sensitivity] [ref. 6], the glucose
infusion rate during a hyperinsulinemic-euglycemic clamp procedure [HECP] [ref. 7], and the insulin suppression test [ref. 8]),
have also been used to determine MHO (9–24). In some studies,
even people with impaired glucose tolerance, T2D, and history of
CVD were considered metabolically healthy because they did not
have a sufficient number of the specified metabolic abnormalities
to be identified as MUO (15, 25–28). Accordingly, people who are
reported as having MHO are often not truly healthy, but simply
have fewer cardiometabolic abnormalities than those defined as
MUO. Therefore, a more rigorous and universally accepted definition of MHO is needed to determine the true prevalence and longterm consequences of MHO and to conduct studies elucidating
the mechanisms that protect some people with obesity from the
adverse metabolic effects of excess body fat.
We propose a set of robust criteria to identify people with
MHO (Table 2), based on (a) the absence of cardiometabolic
diseases, (b) a healthy cardiometabolic blood profile, (c) normal
blood pressure, (d) normal intrahepatic TG content, and (e) normal insulin sensitivity. We have divided these criteria into those
that can be readily obtained in a typical outpatient clinical setting
(basic criteria) and those that require more sophisticated testing
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Table 1. Examples of variability in criteria used to identify metabolically healthy obesity
Cutoff for abnormal values
Blood pressure (mmHg)
≥130/85
>130/85
>140/90
Blood pressure medications
Fasting TG (mg/dL)
≥150
Total cholesterol (mg/dL)
≥200
LDL-cholesterol (mg/dL)
≥130
HDL-cholesterol (mg/dL)
<40 in men or <50 in women
<50 in men and women
<40 in men and women
Lipid medications
Fasting TG/HDL-cholesterol ratio
>1.65 in men or >1.32 in women
Fasting glucose (mg/dL)
≥100
>100
≥126
100–125
Glucose 2-h into oral glucose tolerance test (mg/dL)
≥200
Diabetes medications
Waist circumference (cm)
>102 in men or >88 in women
HOMA-IR
≥75th percentile in study population
>1.95
≥2.5
>5.13 (i.e., ≥90th percentile in study population)
C-reactive protein (mg/L)
≥90th percentile in study population
Metabolically healthy

Wildman
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≤1 of above

–
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≤2 of above

–
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–
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Examples of other criteria used to identify MHO include: (a) Absence of hypertension, dyslipidemia, type 2 diabetes, and cardiovascular disease (82). (b) ≤2
of the National Cholesterol Education Program (NCEP) adult treatment panel (ATP) III metabolic syndrome criteria: waist circumference >102 cm in men
and >88 cm in women; systolic blood pressure ≥135 mmHg or diastolic blood pressure ≥85 mmHg; fasting plasma glucose concentration ≥110 mg/dL; HDL-C
concentration <40 mg/dL in men and <50 mg/dL in women; fasting plasma TG concentration ≥150 mg/dL; or treatment with antihypertensive, lipidlowering, or glucose-lowering medications (4). (c) ≤2 of the NECP ATP III metabolic syndrome criteria revised by the American Heart Association/National
Heart, Lung, and Blood Institute (AHA/NHLBI) scientific statement (184) to redefine abnormal fasting glucose concentration as ≥100 mg/dL. (d) ≤2 of the
AHA/NHLBI metabolic syndrome criteria revised to define waist circumference cutoff values based on population and country-specific standards (185).
(e) ≤1 metabolic syndrome criteria excluding waist circumference (33, 38). (f) Zero metabolic syndrome components, except for waist circumference (50,
186). (g) Plasma C-reactive protein concentration <3 mg/L in addition to different metabolic syndrome components with or without criteria for HOMA-IR
and LDL-cholesterol (16, 60). (h) HOMA-IR values: ≤2.7 (16), lowest tertile in participants with obesity (187), <25th percentile (HOMA-IR ≤1.27) (43) or <90th
percentile (47) of participants without diabetes. (i) “Insulin sensitive,” defined as OGTT-derived Matsuda index (6) >2.1 (18); or as ≥75th percentile of people
with obesity (19); or as glucose infusion rate during a hyperinsulinemic-euglycemic clamp procedure of >8 mg/kg lean body mass/min at insulin infusion
rate of 40 mU/m2 body surface area/min (20), >70 μmol/kg body mass/min at insulin infusion rate of 40 mU/m2 body surface area/min (21), ≥ upper tertile
(≥10.5 mg/kg fat-free mass/min) at insulin infusion rate of 50 mU/m2 body surface area/min (22), or ≥ upper quartile (≥12.62 mg/kg fat-free mass/min)
at insulin infusion rate of 75 mU/m2 body surface area/min (23) of people with obesity in the study; or as steady-state glucose concentration <100 mg/dL
during fixed-rate infusion of octreotide, glucose, and insulin (24).
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Table 2. Proposed criteria for defining metabolically healthy obesity
Basic criteria:
Absence of diagnosis or therapy of
cardiometabolic diseases

Absence of prediabetes, T2D, hypertension, dyslipidemia,
NAFLD, CKD, or CVD; or treatment with blood pressure,
lipid, or diabetes medications

Healthy cardiometabolic profile:
Fasting TG
HDL-C
Fasting glucose
2-hour OGTT glucose
Blood pressure

<95 mg/dL
≥40 mg/dL in men and ≥50 mg/dL in women
<100 mg/dL
<140 mg/dL
<130/85 mmHg

Advanced criteria:
Intrahepatic lipid content (for those not
already diagnosed as having NAFLD)
Insulin sensitivity

<5% of liver volume by imaging or
<5% of hepatocytes with intracellular TG by histology
GIR >8 mg/kg FFM/min during an HECP
(insulin infusion rate: 40 mU/m2/min)

The Journal of Clinical Investigation  

Supplemental Tables 1–4. The prevalence of MHO,
defined as “normal” insulin sensitivity (based on the
HOMA-IR score) and absence of any metabolic syndrome components (excluding waist circumference),
is approximately 7%, whereas half of all people with
obesity can be classified as MHO when defined as ≤2
metabolic syndrome components (including waist circumference). However, it is likely that these results
overestimate the prevalence of MHO in the general
population, because many studies excluded people
with existing cardiometabolic diseases, such as T2D
and CVD (9, 11, 13, 28, 42–44).

Stability of metabolically healthy
obesity over time

The normal decline in metabolic health associated with
increasing age, the metabolic insult of prolonged excess
CKD, chronic kidney disease; CVD, cardiovascular disease; FFM, fat-free mass; GIR,
adiposity, and the tendency to gain weight throughout
glucose infusion rate; NAFLD, nonalcoholic fatty liver disease; HECP, hyperinsulinemicmiddle age likely influence the stability of MHO. The
euglycemic clamp procedure; OGTT, oral glucose tolerance test; T2D, type 2 diabetes.
data from longitudinal studies suggest that approximately 30% to 50% of people with MHO convert to
MUO after 4 to 20 years of follow-up (25, 28, 42, 45–
48). The major factors associated with the conversion of MHO to
available in a research setting (advanced criteria). We propose a
MUO are a decline in insulin sensitivity and an increase in fasting
lower plasma TG concentration “cut-point” than that used for
blood glucose (49). The risk of transitioning from MHO to MUO
diagnosing the metabolic syndrome (i.e., <95 mg/dL vs. <150
is greater in those with a high BMI, older age, evidence of more
mg/dL), based on the plasma TG concentration that marks the
severe metabolic dysfunction (i.e., number of abnormal metabolic
point of transition from large buoyant LDL particles to highly
criteria and values that are closer to the upper limit of the normal
atherogenic, small, dense LDL particles (29). We also propose
range, and the presence of hepatic steatosis) (28, 50–52), a poor
the inclusion of an assessment of insulin sensitivity, defined as
lifestyle index (a composite of diet composition, leisure time physthe glucose infusion rate needed to maintain euglycemia during
ical activity, and cigarette smoking) (53), and weight gain during
an HECP, because many people with obesity who are resistant
the observation period (54, 55).
to insulin can have a normal fasting plasma glucose concentration and normal oral glucose tolerance due to a compensatory
increase in plasma insulin (30). We chose a glucose infusion rate
Clinical outcomes of metabolically healthy
cutoff value that was used previously to define MHO (20) and is
versus unhealthy obesity
similar to the mean value reported in people with a BMI of 25 kg/
In general, the risks of T2D, CVD, and all-cause mortality are
m2 who are metabolically healthy (31).
greater in people with MUO than in those with MHO and greater
in those with MHO than in those who are metabolically healthy
and lean (MHL) (14, 28, 56–60). Moreover, the risks of these
Prevalence of metabolically healthy obesity
adverse outcomes are directly related to the number and severity
The prevalence of MHO depends on the criteria used to define
of metabolic abnormalities (57, 61–66).
metabolic health, whether people with T2D or CVD were excluded from the cohort a priori, and the sex, age, BMI range, and
racial or ethnic background of the study population. Differences
Type 2 diabetes
in these variables are likely responsible for the large variability in
The data from most studies show that the risk of developing T2D
reported prevalence, ranging from 6% (32) to 60% (33) of adults
is 5- to 20-fold greater in people with MUO than in those who are
with obesity when the criteria for metabolic health were based on
MHL (56). The risk of developing T2D is much lower in those with
measured variables (see Supplemental Tables 1–4; supplemental
MHO than MUO, but is still about 4-fold greater than in those
material available online with this article; https://doi.org/10.1172/
who are MHL (56), and is directly related to the number of metJCI129186DS1), and up to 75% when based primarily on selfabolic abnormalities at baseline (61–63). In studies with a 6-year
reported data (34). In general, MHO is more common in women
follow-up, the risk of developing T2D relative to MHL individuthan in men (35–38), in younger than in older adults (35, 36, 39),
als was still increased in people with MHO without any metabolic
in people with BMIs less than 35 kg/m2 than in people with BMIs
syndrome components at baseline (61), but was not increased
when metabolic status remained stable throughout the study (67).
of 35 kg/m2 or higher (40), and in people of European ancestry
than in those from Africa, South America, and South Asia (Indian
ancestry) (39, 41). An estimate of the prevalence of MHO based
Cardiovascular disease
on the stringency of selection criteria from studies conducted in
The risk of CVD events (new-onset angina, fatal and nonfatal
North American and European cohorts is shown in Figure 1 and
myocardial infarction, sudden cardiac death, fatal and nonfatal
3980
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Selected characteristics of metabolically healthy
and unhealthy obesity

Figure 1. Estimated prevalence of metabolically healthy and metabolically unhealthy obesity among people with obesity in North America
and Europe based on the number of metabolic syndrome criteria and an
assessment of insulin sensitivity (using the homeostasis model assessment of insulin resistance [HOMA-IR] score). Data were derived from 33
studies involving a total of 123,548 people with obesity as described in
the Supplemental Material (available online with this article; https://doi.
org/10.1172/JCI129186DS1).

heart failure, and peripheral vascular disease) is lower in people
with MHO than in those with MUO, but is still higher in people
with MHO than in those who are MHL (57–59). A meta-analysis
that pooled data from 18 studies followed over a median of 10
years found that the risk of CVD events was about 50% greater in
people with MHO at baseline than in people who were MHL (14).
The risk of developing CVD events is directly associated with the
number of metabolic abnormalities at baseline (57) and whether
the MHO phenotype remains stable or converts to MUO (28). For
example, in one study, the risk of CVD events in participants who
maintained a stable MHO phenotype over a median of 12 years
was not different from that in participants who were MHL (28).
All-cause mortality
The risk of all-cause mortality is less in people with MHO than in
people with MUO (60). The risk of all-cause mortality in people
with MHO relative to those who are MHL depends on the number and severity of metabolic abnormalities and the stability of
metabolic health (64–66). The combined data from five large
cohort studies that followed participants for an average of 13
years found that people with MHO and no metabolic syndrome
components (excluding waist circumference) did not have an
increased risk of all-cause mortality compared with the MHL
group; however, the risk of all-cause mortality was greater in
participants with MHO versus MHL when participants with one
abnormal metabolic risk factor (excluding waist circumference)
were included in the MHO group (66).

The characteristics that have been associated with MUO are
shown in Figure 2. Among these features, multiorgan insulin resistance (impaired insulin-mediated suppression of hepatic glucose
production, suppression of adipose tissue lipolytic activity, and
stimulation of muscle glucose uptake) is likely the most important
underlying factor responsible for the development of cardiometabolic diseases (68). In people without diabetes, whole-body insulin sensitivity, assessed with the HECP, is inversely correlated
with BMI; however, there is considerable heterogeneity in insulin
sensitivity at any given BMI value so that a small subset of people
with obesity are as insulin sensitive as people who are lean (31, 69).
Insulin sensitivity is greater in people with MHO than in those with
MUO, and many participants identified as having MHO are more
insulin resistant than those who are MHL, manifested by greater
fasting plasma insulin concentrations, blood glucose concentrations during an oral glucose tolerance test, and HOMA-IR values
(9, 27, 70–72). The factors responsible for the greater preservation
of insulin action in people with MHO than in those with MUO are
not clear, but could be related to differences in potentially modifiable lifestyle factors and alterations in adipose tissue biology (73).
In this section we review each of these areas with a major focus on
adipose tissue biology.
Lifestyle factors
Diet. The relationship between dietary intake and metabolic
health has been evaluated in large population studies by using the
food frequency questionnaires or 24-hour dietary recall data. The
ability of these methods to reliably assess dietary intake has been
questioned (74, 75). The results from most studies do not show a
difference in total dietary energy intake or macronutrient distribution between people with MHO and MUO (76–78). In addition,
data from the US National Health and Nutrition Examination
Survey showed no difference in diet quality, assessed as the consumption of Mediterranean-style and DASH-style diets, between
people with MHO and MUO (79). A higher total Healthy Eating
Index score, which assesses diet quality in relation to the 2005
US National Dietary Guidelines, was found in MHO than in MUO
women who were 19–44 years old, but this score was not different
in women with MHO and MUO who were 45–85 years old or in
adult men with MHO and MUO (80). There is evidence from some
(76, 77, 80–82) but not all (27, 77) studies that the consumption of
specific types of foods differs between MHO and MUO groups;
MHO was associated with a lower intake of sugar, sugar-sweetened beverages, and saturated fat and a higher intake of whole
fruits, whole grains, and protein from vegetable sources.
Physical activity and cardiorespiratory fitness. Increased physical activity improves insulin sensitivity and metabolic syndrome
abnormalities (83). The amount and intensity of physical activity
in MHO and MUO populations have been studied by the doubly
labeled water method, accelerometry, and activity questionnaires.
No differences in total daily energy expenditure or energy expended during physical activity, measured by the doubly labeled water
method, were detected between people with MHO and MUO
(20, 84). In contrast, studies that measured physical activity by
using accelerometers or questionnaires showed that people with
jci.org   Volume 129   Number 10   October 2019
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Figure 2. Putative characteristics of people with metabolically unhealthy obesity that are distinct from those of people with metabolically healthy
obesity. However, the evidence to support a difference in many of these characteristics between people with MUO and MHO is not definitive because of
inadequate data or conflicting results from different studies.

MHO spend more time in moderate to vigorous physical activities
and less time in sedentary activities than people with MUO (35,
85–87). The results from a meta-analysis that pooled data from
15 studies found that cardiorespiratory fitness, assessed as maximum oxygen consumption during exercise, was greater in people
with MHO than in those with MUO (87), but the average difference between groups was very small (1–2 mL/kg/min).
Sleep. Insufficient sleep duration and poor sleep quality have
adverse effects on metabolic function (88) and are associated
with obesity (89, 90). The results from nearly all studies that have
assessed sleep duration and quality in people with MHO and MUO
are not adequate to reliably evaluate potential differences between
people with MHO and MUO, because the data are derived from
questionnaires rather than direct assessments of sleep duration
and quality. In general, sleep duration and the proportion of short
sleepers (<7 hours per day) were not significantly different in people with MHO and those with MUO (72, 85, 91–93).
Adipose tissue biology
The expansion of adipose tissue and TG mass with weight gain
(a) is not uniformly distributed among different adipose tissue
depots and the liver; (b) is due to an increase in adipocyte size or
adipocyte number, or both; (c) requires adequate blood supply to
maintain tissue oxygenation; (d) promotes extracellular matrix
(ECM) remodeling to provide the scaffolding needed to support
the expanded adipocyte mass; (e) causes an increase in adipose
tissue–resident immune cells and both adipose tissue and system3982
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ic markers of inflammation; (f) affects adipocyte lipolytic activity
and the rate of release of fatty acids into the circulation; and (g)
alters the production of adiponectin, the major adipocyte secretory protein involved in regulating insulin sensitivity.
Body composition. Percentage body fat is not different in people with MHO and MUO when the groups are matched on BMI
and sex (19–21, 23, 94). However, there are marked differences in
adipose tissue distribution and intrahepatic TG content between
MHO and MUO cohorts. People with MHO have less intraabdominal adipose tissue (IAAT) than people with MUO (21, 23,
76, 95–97), but still have two to three times more IAAT than people
who are MHL (19, 22). Although women with MHO tend to have a
greater amount of lower-body (subcutaneous thigh or leg) fat mass
than women with MUO (20, 48, 95, 96), lower-body fat mass is
not different between men with MHO and MUO (48, 96). Intrahepatic TG content is greater in people with MUO than in those
with MHO (98), and those with steatosis have greater multiorgan insulin resistance (99) and higher plasma TG concentrations
(100) than those with normal intrahepatic TG content, even when
matched on BMI, percentage body fat, and IAAT volume (101).
Taken together, these data show that excess adiposity per se is not
responsible for the differences in metabolic health between people with MHO and MUO, but differences in adipose tissue distribution distinguish between MHO and MUO phenotypes.
Adipogenesis and lipogenesis. Studies that assessed adipogenesis/lipogenesis in people with MHO and MUO have focused
primarily on the subcutaneous abdominal adipose tissue (SAAT)

The Journal of Clinical Investigation  

R E V IE W S E R IE S: MECHA NISMS UNDE R LYING THE ME TA BO L IC SYND ROM E

depot. The relationship between adipogenesis (i.e., proliferation and differentiation of preadipocytes) in SAAT and metabolic health is unclear. Adipogenic capacity in SAAT, assessed by in
vitro differentiation assays and expression of genes involved in
preadipocyte proliferation and differentiation, is greater in people
with MHO than in those with MUO (102–105). However, adipocyte proliferation rates, determined in vivo by measurement of the
incorporation of ingested deuterium into the DNA of adipocytes
isolated from SAAT, have been reported as either not different
(106) or lower (107) in people who were overweight/obese and
insulin sensitive than in people who were overweight/obese and
insulin resistant. The capacity for lipogenesis in SAAT, assessed
as expression of genes involved in lipogenic pathways (CD36,
GLUT4, ChREBP, FASN, and MOGAT1), is greater in people with
MHO than MUO (101, 102, 108, 109). Moreover, the expression
of these genes is positively correlated with insulin sensitivity (108,
109), and increases more after moderate weight gain in people
with MHO than MUO (110). Collectively, these data refute the
notion that impaired adipogenesis contributes to insulin resistance in people with MUO (111), but demonstrate that increased
adipose tissue gene expression of lipogenic pathways is associated
with metabolic health.
Adipocyte size. Adipocyte size is typically measured by one of
three methods: (a) histological analysis of adipose tissue; (b) collagenase digestion of adipose tissue to generate free adipocytes
that are measured by microscopy; and (c) adipose tissue osmium
tetroxide fixation and cell size analysis using microscopy or a Multisizer Coulter Counter. The median adipocyte diameters in SAAT
measured by each of these methods correlate with whole-body
adiposity (112). However, the frequency of small cells (20–50 μm
range) varies considerably among the three methods (112). The
highest frequency of these small cells, which are believed to be
immature or differentiating adipocytes, but could be large lipidladen macrophages (113), is observed when cell size is assessed by
the osmium fixation method (112, 114). The results from several
studies show an inverse correlation between average or peak subcutaneous abdominal adipocyte size and insulin sensitivity, and
that adipocyte size is greater in people with MUO than in those
who are metabolically healthier (21, 114–118). However, other
studies did not detect a difference in average subcutaneous adipocyte size in MHO and MUO participants (102, 105, 119). Two studies identified two distinct populations of adipocytes based on size
and found a higher ratio of small to large subcutaneous abdominal
adipocytes in people who were insulin resistant than in those who
were insulin sensitive (102, 114). In summary, the majority of studies show that mean adipocyte size is smaller in people with MHO
than MUO. However, the observation that adipose tissue contains distinct small- and large-cell populations with variable cell
numbers confounds the interpretation of overall mean cell size.
Accordingly, more sophisticated analytical methods that quantify
adipocyte cell sizes and number are needed.
Oxygenation. The oxygenation of adipose tissue depends on
the balance between the rate of oxygen delivery to adipose tissue
cells (adipocytes, preadipocytes, mesenchymal stem cells, fibroblasts, vascular endothelial cells, and immune cells) and their rate
of oxygen consumption. The delivery of oxygen to adipose tissue
is likely lower in people with obesity than in people who are lean

because of decreased systemic arterial oxygen content associated
with pulmonary dysfunction (120, 121), decreased adipose tissue
capillary density and perfusion (122–125), an increased number of
interstitial immune cells (126), and possibly greater oxygen diffusion distance due to hypertrophied adipocytes and increased ECM
content (127). However, the adequacy of adipose tissue oxygenation in people with obesity is not clear, because interstitial adipose tissue oxygen partial pressure (pO2), not intracellular pO2, is
measured and because of conflicting data from different studies
depending on the method used (120, 123–125, 128–130). Studies
that used a Clark-type electrode or a fiber optic system to assess
interstitial SAAT pO2 in situ found that pO2 was lower in people
who are obese than in those who are lean (123, 124, 128, 129). In
contrast, studies that used an optochemical sensor to measure pO2
in SAAT interstitial fluid extracted by microdialysis ex vivo found
that pO2 was higher in people with obesity than in those who were
lean despite decreased adipose tissue blood flow in people with
obesity, suggesting decreased adipose tissue oxygen consumption
in the obese group (125, 130). A direct assessment of arteriovenous oxygen balance across SAAT demonstrated that both oxygen
delivery and consumption were decreased in people with obesity
compared with those who were lean or overweight; however, obesity was not associated with evidence of adipose tissue hypoxia,
assessed as oxygen net balance and the plasma lactate-to-pyruvate ratio across SAAT (120). We are aware of three studies that
evaluated interstitial SAAT pO2 in people with MHO and MUO.
Two studies measured pO2 in situ and found that pO2 was greater (128), or not different (129), in the MHO compared with MUO
groups. The third study measured pO2 ex vivo in SAAT interstitial
fluid extracted by microdialysis and found it was lower in MHO
than in MUO (130). We are not aware of any studies that evaluated metabolic indicators of adipose tissue hypoxia, namely adipose
tissue HIF1α protein content, in people with MHO and MUO. In
summary, currently there is not adequate evidence to conclude
there is a physiologically important decrease in adipose tissue oxygenation in people with MUO compared with MHO.
ECM remodeling and interstitial fibrosis. The ECM of adipose
tissue is composed of structural proteins (primarily collagens I, III,
IV, V, and VI) and adhesion proteins (fibronectin, elastin, laminin,
and proteoglycans). Compared with people who are lean, people with obesity have increased expression of genes for collagen
I, IV, V, and VI and histological evidence of increased fibrosis,
particularly pericellular fibrosis in omental adipose tissue and
SAAT (131–135). In addition, we recently found that adipose tissue
expression of connective tissue growth factor (CTGF), a matricellular protein that regulates tissue fibrosis, is positively correlated
with body fat mass and inversely correlated with indices of wholebody, liver, and skeletal muscle insulin sensitivity (136). Adipose
tissue expression of collagen genes and collagen content are also
inversely correlated with insulin sensitivity in people with obesity,
and decrease with weight loss (129, 137–139). These data support
the notion that adipose tissue fibrosis is associated with MUO, as
has been demonstrated in rodent models (140).
Immune cells and inflammation. Obesity is typically associated
with chronic, low-grade, noninfectious inflammation, which has
been purported to be a cause of insulin resistance (141, 142). It
has been proposed that alterations in adipose tissue immune cells
jci.org   Volume 129   Number 10   October 2019
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are an important cause of the chronic inflammation and insulin
resistance associated with obesity (141, 143). Macrophages are the
most abundant immune cell in adipose tissue, and adipose tissue
macrophage content is increased in people with obesity compared
with people who are lean (126). Moreover, adipose tissue macrophage content and crown-like structures (macrophages surrounding an extracellular lipid droplet) are greater in both SAAT and
IAAT in people with MUO than in those with MHO; the increase
in macrophage content is primarily due to an increase in M1-like
(proinflammatory) macrophages (21, 144–147). Differences in adipose tissue proinflammatory CD4+ T lymphocytes between people
with MHO and MUO have also been reported. The percentages of
total CD4+ T cells that are proinflammatory Th17 and Th22 cells
are lower in both SAAT and IAAT in people with MHO than MUO
(22, 148). In addition, in one study, antiinflammatory CD4+ Th2
cells in both SAAT and IAAT correlated directly with insulin sensitivity, assessed by the insulin suppression test (149).
In conjunction with the alterations in adipose tissue immune
cells, adipose tissue expression of inflammation-related genes is
also greater in people with MUO than in those with MHO (21, 129,
145, 146, 150, 151), but there is inconsistency in the specific genes
that are upregulated among studies, and the differences in gene
expression markers between MUO and MHO groups are often
small (21, 129, 145, 146, 150, 151). Plasma concentrations of markers of inflammation, primarily C-reactive protein, plasminogen
activator inhibitor-1 (PAI-1), IL-6, and TNF-α, are either higher in
those with MUO than MHO (21, 23, 42, 96, 152–154) or not different between the two groups (155–157). The variability in results is
likely related to the definitions used to identify MUO and MHO, the
specific inflammatory markers evaluated in different studies, and
the sample size needed for adequate statistical power because of
small mean differences in plasma concentrations between groups.
The variability and small difference in adipose tissue expression of inflammatory markers in people with MHO and MUO and
both the variability and small differences in plasma markers of
inflammation between people with MUO and MHO question the
importance of adipose tissue production and secretion of inflammatory cytokines in mediating the difference in systemic insulin
resistance observed in people with MUO and MHO. Nonetheless,
it is possible that other immune cell–related mediators, such as
adipose tissue macrophage-derived exosomes (158), are involved
in the pathogenesis of metabolic dysfunction.
Lipolytic activity. Acute experimental increases in plasma free
fatty acid (FFA) concentration, induced by infusion of a lipid emulsion, impair insulin-mediated suppression of hepatic glucose production and insulin-mediated stimulation of glucose disposal in
a dose-dependent manner (159, 160). However, the influence of
endogenous adipose tissue lipolytic activity and plasma FFA concentration on insulin sensitivity in people with obesity is not clear
because of conflicting results from different studies. Specifically,
the basal rates of FFA release into the systemic circulation and plasma FFA concentration have been reported as either greater (21, 161,
162) or not different (101, 163, 164) in people who are overweight/
obese and insulin resistant compared with those who are insulin
sensitive. The importance of circulating FFA as a cause of insulin
resistance in MUO is further questioned by studies that found no
difference in basal, postprandial, and 24-hour plasma FFA concen3984
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trations in people with obesity compared with those who are lean
and more insulin sensitive (122, 165). The reason(s) for the differences between studies are not clear, but could be related to the
considerable individual day-to-day variability in FFA kinetics and
plasma FFA concentration and differences in compensatory hyperinsulinemia and insulin-mediated suppression of adipose tissue
lipolytic rate in people with insulin resistance (122, 165, 166). Differences in the percentage of women between study cohorts will also
affect the comparison of FFA kinetics and concentrations between
MHO and MUO groups, because the rate of the appearance of FFA
in the bloodstream in relationship to fat-free mass or resting energy
expenditure is greater in women than in men (167, 168), yet muscle
(169) and liver (170, 171) insulin sensitivity are greater in women.
Taken together, these studies suggest that differences in subcutaneous adipose tissue lipolytic activity do not explain the differences in
insulin sensitivity between people with MHO and MUO. However,
it is still possible that differences in lipolysis of IAAT and portal vein
FFA concentration (172) or differences in the effect of FFA on tissue
(muscle or liver) insulin action contribute to the differences in insulin resistance between the two groups.
Adiponectin. Adiponectin, the most abundant protein secreted
by adipose tissue, is inversely associated with percentage body fat
and directly associated with insulin sensitivity in both men and
women (173). Plasma adiponectin concentrations are often higher
in people with MHO than MUO (12, 174–176). The reasons for the
lower adiponectin concentration in MUO than MHO are unclear
but could be related to chronic hyperinsulinemia in people with
MUO, which suppresses adipose tissue adiponectin production
(177, 178), thereby generating a feed-forward cycle of decreased
adiponectin secretion caused by insulin resistance and increased
insulin resistance caused by decreased adiponectin secretion.

Conclusions

There is considerable heterogeneity in the metabolic complications associated with obesity. About 50% of people with obesity
are metabolically healthy when healthy is defined as the absence
of the metabolic syndrome, whereas only approximately 5% are
metabolically healthy when healthy is defined as the absence of
any metabolic syndrome components and normal insulin sensitivity assessed by HOMA-IR. The risk of developing cardiometabolic
diseases in people with obesity is directly related to the number
and severity of metabolic abnormalities. Accordingly, people with
MHO are at lower risk of future T2D and CVD than people with
MUO, but most people with MHO are at a higher risk than people who are MHL. However, people with MHO who do not have
any metabolic abnormalities and remain MHO over time might
not have an increased risk of developing cardiometabolic diseases
compared with those who are MHL. These findings support the
need for a rigorous and universal definition of MHO (proposed in
Table 2) to allow reliable integration of data from different studies
and facilitate research needed to identify the factor(s) involved in
protecting some people with obesity from the adverse metabolic
effects of excess adiposity.
The precise mechanisms responsible for preserved metabolic health in people with MHO are not known. The studies to date
have not demonstrated important differences in lifestyle factors
(diet composition, physical activity, and sleep) between MHO and
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MUO. However, this does not mean that lifestyle is not an important regulator of metabolic health, but rather underscores the limitations in the assessment of lifestyle factors and in the definition
of MHO in the current studies. It is likely that there is an important
genetic contribution to the metabolic phenotype in people with
obesity. Although GWAS have identified genetic variants that are
associated with increased adiposity in conjunction with a healthy
metabolic profile (179), a better understanding of the genetic
aspects of MHO will likely provide new insights into the mechanisms responsible for metabolic disease. The influence of the
gut microbiome on metabolic health is a rapidly emerging area of
research. The potential for adverse and beneficial effects of the gut
microbiome on metabolic health could be related to the composition and diversity of the microbiota and the ability of the gut barrier function to prevent leakage of bacteria and bacterial products
across the intestine (180–182). In addition, studies conducted in
human subjects demonstrate an increase in markers of inflammation and interstitial fibrosis in adipose tissue in people with MUO
compared with MUO. However, these studies are not able to determine whether these abnormalities are a cause or a consequence of
insulin resistance and related metabolic dysfunction.
The heterogeneity in the metabolic complications associated
with obesity has important clinical implications, particularly in
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